Malignant hyperthermia is a life-threatening reaction to some anesthetics in people with disease-causing variants in RyR1, a channel that releases calcium inside muscle cells. Dantrolene has long been used to treat the condition, but its binding site and mechanism had been unclear.

Using cryo-electron microscopy, the researchers mapped dantrolene’s binding site and compared RyR1 with the channel bound to the trigger compound 4-chloro-m-cresol. Dantrolene binds alongside ATP or ADP in a region called the RY12 domain, causing a shape change that is linked to closure of the channel’s pore.